Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 23, 2025, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its
Milan, Italy and Morristown, NJ, USA – March 11, 2025 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused
Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea
Myung In Pharm
Ad hoc announcement pursuant to Art. 53 LR
Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones,
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia
Leading schizophrenia
Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
